Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
19269824
DOI
10.1016/j.nmd.2009.01.005
PII: S0960-8966(09)00008-X
Knihovny.cz E-resources
- MeSH
- Databases as Topic organization & administration trends MeSH
- Genetic Carrier Screening methods MeSH
- Child MeSH
- Muscular Dystrophy, Duchenne epidemiology genetics therapy MeSH
- Genetic Predisposition to Disease genetics MeSH
- Genetic Testing methods trends MeSH
- Clinical Trials as Topic methods trends MeSH
- Humans MeSH
- Mutation genetics MeSH
- DNA Mutational Analysis methods trends MeSH
- Registries statistics & numerical data MeSH
- Data Collection methods MeSH
- Muscle Proteins genetics MeSH
- Patient Selection MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Slovakia epidemiology MeSH
- Names of Substances
- Muscle Proteins MeSH
Effective planning of clinical trials requires an appropriate number of patients who fulfil given inclusion criteria. In the case of so called "orphan" diseases, such as Duchenne and Becker muscular dystrophy (DMD/BMD), the number of suitable patients within one country is usually limited. We developed a detailed registry of Czech and Slovak DMD/BMD patients which may contribute to cooperation on the European level. The registry uses internet and database technologies with a multilevel architecture. Patients may view their own data. As of May 2008, 163 patients have been registered in the database. The registry provides a detailed phenotypic and genotypic description of patients. The main purpose of such a registry is the time-effective recruitment of eligible patients for a clinical trial or therapy and may allow the anticipation of possible future effects of appropriate therapy on individual patients. The importance of the DMD/BMD patient registries has recently also been rising with new clinical trials focused on mutation-specific approaches. Other outputs include assessment of epidemiology, phenotype and genotype relationships, or standards of care.
References provided by Crossref.org